Zentalis Pharmaceuticals ZNTL 深 沪
已收盘 03-27 16:00:00 美东时间
2.10
-0.570
-21.35%
华盛通- 最 高2.61
- 今 开2.60
- 成交量 114.53万股
- 最 低 2.09
- 昨 收 2.67
- 总市值 1.36亿
- 52周最高 3.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.01
- 委 比 -2.38%
- 总股本 6475.08万
- 历史最高 87.19
- 量 比 2.68
- 振 幅 19.48%
- 历史最低 1.01
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
7分钟前
Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target
Guggenheim analyst Michael Schmidt reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $6 price target.
03-27 20:47
Zentalis Pharma Q4 EPS $(0.49) Misses $(0.44) Estimate.
Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.44) by 10.36 percent. This is a 25.76 percent increase over losses of $(0.66) per share from
03-27 04:39
Zentalis Pharmaceuticals GAAP EPS of -$1.91
Zentalis Pharmaceuticals press release (ZNTL): FY GAAP EPS of -$1.91. Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, the Company had cash, cash equivalents and marketable s...
03-27 04:33
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Zentalis Pharmaceuticals announced two poster presentations at the 2026 AACR Annual Meeting, highlighting Azenosertib's potential as a combination therapy for Triple-Negative Breast Cancer and its biomarker-driven approach for Cyclin E1-positive ovarian cancer. Azenosertib, a WEE1 inhibitor, targets cell cycle checkpoints to induce cancer cell death. The company emphasizes Cyclin E1 protein overexpression as a predictive biomarker for poor progno...
03-17 20:30
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in three upcoming investor conferences: Oppenheimer's 36th Annual Healthcare Life Sciences Conference (Feb. 25, 2026, virtual), TD Cowen's 45th Annual Health Care Conference (March 3, 2026, Boston), and Leerink Partners' Global Healthcare Conference (March 9, 2026, Miami). Live webcasts and recordings will be available on the company's website under the "Events & Present...
02-18 13:00
Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares
Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
02-05 09:28
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit Zentalis Pharmaceuticals Inc. will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Disclaimer: This news brief was cr
02-04 05:05
Zentalis outlines 2026 milestones for azenosertib program
Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On January 6, 2026...
01-10 06:49
